Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation [PDF]
BMC Cancer, 2019 Background Chemoresistance is an obstacle to the successful treatment of nasopharyngeal carcinoma (NPC). Lapatinib is a targeted tyrosine kinase inhibitor therapeutic drug also used to treat NPC, but high doses are often required to achieve a result.
Sathid Aimjongjun +7 more
doaj +2 more sources
Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
PLoS ONE, 2018 HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation.
Sharad Verma +5 more
doaj +2 more sources
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Breast Cancer: Targets and Therapy, 2012 Sara A Hurvitz, Reva KakkarDepartment of Medicine, University of California, Los Angeles, CA, USAPurpose: This review aims to present the preclinical and clinical data regarding efficacy and safety of lapatinib alone and in combination with other agents ...
Hurvitz SA, Kakkar R
doaj +1 more source
pharma-kritik, 2009 The human epidermal growth factor receptor (HER) family of growth factor receptor tyrosine kinases (RTKs) plays an important role in the biology of many cancers. In breast cancer, HER2 and its homo- or heterodimerization with HER1 or HER3 are essential for cancer cell growth and survival. Patients overexpressing HER2 have a poor prognosis, which can be
Schneider-Merck, Tanja, Trepel, Martin
+5 more sources
Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer [PDF]
, 2015 Acquired resistance to lapatinib, an inhibitor of EGFR and HER2 kinases, is common. We found that reactivation of EGFR, HER2 and HER3 occurred within 24 hours of lapatinib treatment after their initial dephosphorylation.
Harris A. L. +6 more
core +4 more sources
Investigating the Effect of Lapatinib on the Performance of Sonodynamic Therapy Against Prostate Cancer via Inhibition of the ABCG2 Efflux System [PDF]
Pharmacol Res PerspectABSTRACT Sonodynamic therapy (SDT) is an emerging site specific and minimally‐invasive modality for cancer treatment. Its efficacy heavily relies on the accumulation and retention of systemically‐administered sensitizing agents within tumor cells.
Wang Y, Masood H, Nomikou N.
europepmc +2 more sources
The involvement of hepatic cytochrome P450s in the cytotoxicity of lapatinib [PDF]
, 2023 Lapatinib, an oral tyrosine kinase inhibitor used as a first-line treatment for HER2-positive breast cancer, has been reported to be associated with hepatotoxicity; however, the underlying mechanisms remain unclear.
si Chen +21 more
core +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Dermatological Adverse Events Associated With Lapatinib Treatment in Dogs With Urothelial Carcinoma: A Retrospective Study. [PDF]
Vet DermatolLapatinib is widely used in human oncology; however, dermatological adverse events (DAEs) are common and have been correlated with treatment efficacy. In veterinary medicine, lapatinib use in combination with piroxicam has been shown to be effective in treating canine urothelial carcinoma (UC); however, the incidence and prognostic significance of DAEs
Horita K, Yonezawa T, Momoi Y, Maeda S.
europepmc +2 more sources
Lapatinib in the Treatment of Hormone Receptor-Positive/ErbB2-Positive Breast Cancer [PDF]
, 2010 In women with estrogen receptor(ER)- and ErbB2(HER2)-positive breast cancer, a vicious cycle is established between ER mechanisms of action and the growth factor receptor network, leading to enhanced cell proliferation and endocrine resistance.
Bauerfeind, Ingo +2 more
core +1 more source